Enlarge this image
The federal Medicaid program had accused Mylan of underpaying required rebates for the EpiPen, which is used to reverse serious allergic reactions.
Drew Angerer/Getty Images
hide caption
toggle caption
Drew Angerer/Getty Images
Drugmaker Mylan N.V. announced Friday that it had reached a $465 million settlement with the U.S. Justice Department and other government agencies to resolve questions over rebates required by the Medicaid program. The deal settles allegations by the Centers for Medicare and Medicaid Services that Mylan had misclassified the EpiPen as a generic drug and had not paid the appropriate rebates that are required by law. Andrew Slavitt, the acting head of CMS, detailed the allegations in a letter to Sen. Ron Wyden, D-Ore., this week. Slavitt told Wyden that Mylan had misclassified EpiPen as a “non-innovator” or generic drug, when it should have been classified as a brand-name product. Slavitt said …
Go to Source